Released next-generation growth hormone drug

Will the 250 billion won market change?

18% increase compared to the previous year

LG Chem Eutropin → Eutropin S generation replacement, sales increased from 42.1 billion won → 50 billion won

The domestic growth hormone drug market, which is rapidly growing, has faced a variable with the release of new products by major companies.

 

LG Chem, the No.

 

1 company in the market, replaced the existing Eutropin with the next-generation product, Eutropin S, further solidifying its leading position, followed by Dong-A ST and Pfizer.

 

In particular, Pfizer plans to add NGENLA, a once-a-week medication, to its lineup starting next month.

 

Depending on the success of this product, considerable changes are expected in the growth hormone market in the future.

 

Expected to exceed 250 billion won in the growth hormone market, successful replacement of LG Chem’s Eutropin S generation.

 

According to IQVIA, a pharmaceutical market research institute, on the 29th, the size of the domestic growth hormone drug market in the first half of last year was 135.6 billion won.

 

It increased by 18% from 114.6 billion won in the first half of last year.

 

The domestic growth hormone drug market is rapidly growing in recent years.

 

The market, which was worth 145.7 billion won in 2019, exceeded 150 billion won in 2020 and 200 billion won in 2021.

 

Last year, it further expanded to 238.6 billion won.

 

In the case of this year, it recorded 130 billion won in the first half alone and is expected to expand to more than 250 billion won by the end of the year.

 

It was found that related sales of major companies increased together.

 

LG Chem's combined sales of Eutropin and Eutropin S increased by 19% in one year from 42.1 billion won in the first half of last year to 50 billion won in the first half of this year.

 

LG Chem received permission for Eutropin S in April last year.

 

Then, at the end of last year, sales began in earnest.

 

Compared to existing products, the expiration date has been increased from 18 months to 24 months.

 

LG Chem explains that the expiration date has been extended, improving supply stability and making it possible to check the remaining capacity.

 

It is an analysis that it succeeded in a natural generational change with existing products.

 

Sales of Eutropin S increased from 5.5 billion won in the fourth quarter of last year to 19.3 billion won in the first quarter of this year and 19.7 billion won in the second quarter.

 

Existing Eutropin sales decreased to 15.5 billion won, 5.5 billion won, and 4.9 billion won during the same period.

 

In the case of combined sales, it has been on an upward trend since the addition of new products.

 

Pfizer, No.

 

3 in the market, announces the release of NGENLA once a week.

 

LG Chem's Eutropin/Eutropin S, Dong-A ST's Growtropin II, and Pfizer's Genotropin/Genotropin goquick pen are rapidly catching up.

 

In particular, the increase in related sales of the two companies was found to be greater than that of LG Chem, the market leader.

 

Dong-A ST's Growtropin II posted sales of 33.2 billion won in the first half.

 

Compared to 21.2 billion won in the first half of last year, it increased by 57% in one year.

 

Growtropin II, which exceeded 10 billion won in quarterly sales in the first quarter of 2022, exceeded 15 billion won in sales in the first quarter of this year, and quarterly sales are about to reach 20 billion won.

 

Pfizer's Growtropin series is showing even greater sales growth.

 

The combined sales of Growtropin and Genotropin goquick pen increased by 86% in one year from KRW 14.1 billion in the first half of last year to KRW 26.3 billion in the first half of this year.

 

Genotropin, a cartridge-type product, increased by 48% from KRW 8 billion to KRW 11.8 billion, and Genotropin goquick pen, a pen-type product, increased 2.4 times from KRW 6.1 billion to KRW 14.5 billion.

 

It is analyzed that sales of Genotropin goquick pen, a next-generation product, are gradually expanding as the domestic supply of the two products stabilizes after 2020.

 

Pfizer plans to add a new product to its lineup.

 

Pfizer received permission for NGENLA Prefilled Pen Injection in January of this year.

 

This product will be applied for reimbursement from next month.

 

NGENLA is a product that lengthens the half-life by modifying the molecule of Genotropin.

 

If the existing Genotropin was administered daily, NGENLA is administered once a week.

 

However, the indication is limited to the treatment of growth failure in children (3 years of age or older) due to pituitary growth hormone secretion disorders.

 

Pfizer plans to continue supplying Genotropin even if a new treatment is released, as NGENLA has a smaller indication range than Genotropin.

 

In addition, Merck's Saizen increased sales by 27% from 16.1 billion won in the first half of last year to 20.4 billion won in the first half of this year.

 

Sales of Novo Nordisk Norditropin nordiflex plunged from 16.3 billion won in the first half of last year to 1.1 billion won in the first half of this year.

 

Norditropin is known to have been discontinued in Korea since the third quarter of last year.

 

The company initially announced the timing of domestic resupply at the end of November last year but corrected it to say that it is currently undecided.

 

In the first half of the year, sales of Cyzen Korea Scitropin decreased by 8% from 3.8 billion won to 3.4 billion won, and Ferring Zomacton's sales increased from 1.1 billion won to 1.2 billion won.